Contract development and manufacturing organizations (CDMOs) are emerging as global key players within the pharmaceutical industry, and their Nordic presence and offering will give the region both resilience and a

Contract development and manufacturing organizations (CDMOs) are emerging as global key players within the pharmaceutical industry, and their Nordic presence and offering will give the region both resilience and a
The startup company has completed a heavily oversubscribed fundraise. The new funds will be used initially to expand the company’s clinical trial program for its Dermalyser AI-driven support tool in Sweden
Modus Therapeutics has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease. The patent application is based on novel preclinical work
The U.S. Food and Drug Administration has granted the designation for the company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA. In December 2022, Evaxion received FDA approval to proceed
The company has raised an additional 10.6 million SEK to accelerate commercialization of its SiPore health and food supplement portfolio. “In the current climate, the rapid completion and oversubscription of this
The new science city in Reykjavik is set to attract growing companies, foreign investors and even more talent. Despite being one of the world’s smallest capitals, Reykjavik has an innovative
The partnership will include access to the scientific, clinical and drug development expertise of the Leukemia & Lymphoma Society (LLS) as well as a strategic capital equity investment from LLS
AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure’s
Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an
IRLAB Therapeutics has announced that a drug candidate has been nominated from the P003 research project. The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the
Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma
The Series B financing round of HVR Cardio was led by Finnish Innovestor Life Science Fund and Tesi. The Finnish cardiovascular device company HVR Cardio is developing a catheter-based solution CathHELIX, which makes
For six months starting in January 2023 Sweden will hold the Presidency of the Council of the European Union. It is much more than an honorary role, encompassing an opportunity for Sweden to both set new guidelines and see to the implementation of important existing policies.
Ultimovacs has announced the completed recruitment of 118 patients with pleural mesothelioma in the NIPU trial. NIPU is a randomized, multi-center phase II trial initiated and sponsored by Oslo University Hospital with support from
IRLAB Therapeutics has announced the results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). The primary endpoint, change in daily hours of ON-time
Ultimovacs has announced that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The
What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company. Fascinated by the
SwedenBIO has appointed the co-founder and operational manager of Sprint Bioscience, Jessica Martinsson, as its new Director General. “With her entrepreneurial experience and co-founder of a life science company, SwedenBIO
No 04 2022 // Welcome to our 15th Nobel Prize issue! We have decided to return to an old tradition and publish this issue in November, just in time for the glittering Nobel festivities, when the whole world’s attention is drawn to the Nordic region. This year we also have two Nordic (!) Laureates within the field of life sciences, Swedish Svante Pääbo and Danish Morten Meldal.
In addition, we have spoken to Business Region Göteborg’s investment advisor Iris Öhrn, we have found out what’s behind Nordic Biomarker’s recent success and we take a closer look on the critical role of Nordic CDMOs. This issue also includes a commentary about recent trends in healthcare, a perspective about Real-World Data, and interviews with the new CEOs of Industrifonden and SwedenBIO.
This, and much more, in our latest issue – out now!
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
An international team of researchers have combined ideas from biology, computer science and mathematics to explain why evolution seems to favor symmetry. We spoke with Iain Johnston, a professor at
Thanks to a donation of SEK 35 million from financier and philanthropist Rune Andersson, Karolinska Institutet’s research group leader Andrea Carmine Belin will very soon be setting up the world’s
Olink Holding has announced the 2022 winner of the young researchers’ award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain. Novelties in Biomarkers is an annual award
The European Patent Office (EPO) has honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category “Lifetime achievement”, for her seminal work in developing modified messenger
Dr Martin Oeggerli at Micronaut GmBH, Basel, Switzerland, is this year’s winner of the Lennart Nilsson Award. Martin Oeggerli holds a PhD in medical molecular biology. Since 2005, he works